Breast Cancer Screening Market By Test Type (Blood Marker Test, Genetic Test, Imaging Test, Immunohistochemistry Test) , By Gender (Male, Female) By End User (Specialty Clinics, Hospitals, Diagnostic Centers, Other) : Global Opportunity Analysis and Industry Forecast, 2024-2033
The breast cancer screening market was valued at $2.9 billion in 2023, and is projected t%li%reach $6.7 billion by 2033, growing at a CAGR of 8.7% from 2024 t%li%2033.
Breast cancer screening is a critical public health strategy aimed at early detection of breast cancer, the most common cancer among women globally. The primary goal of this preventative measure is t%li%identify cancer at an early stage when it is most treatable. Mammography is the most widely used screening tool, and its regular use has been shown t%li%reduce mortality rates from breast cancer. By detecting tumors early, breast cancer screening increases the chances of successful treatment, improves survival rates, and can help t%li%reduce the need for more aggressive treatments later on.
The growth of the global breast cancer screening market is driven by alarming increase in the global prevalence of breast cancer and rise in awareness and demand for early detection methods. According t%li%a study published in March 2024 by the World Health Organization, approximately 2.3 million women were diagnosed with breast cancer and 670,000 deaths were reported globally in 2022. Furthermore, governments and healthcare organizations are increasingly promoting breast cancer screening through awareness campaigns, subsidies, and organized screening programs, which have encouraged easy access t%li%screening services. According t%li%a study published by the U.S. Centers for Disease Control and Prevention in 2022, approximately 76.4% of women aged 50-74 underwent a mammogram within the past tw%li%years. This statistic reflects the effectiveness of public health campaigns and the accessibility of screening services across the U.S. Moreover, surge in aged women population significantly contributes toward the market growth. This is attributed t%li%the fact that aged women are at higher risk of developing breast cancer due t%li%weakened immune system, accumulation of genetic mutations, and changes in breast tissue. Rise in emphasis on early screening in younger women and development of non-invasive screening methods are the key trends are that further fostering the market growth. However, high cost associated with breast cancer screening, particularly advanced technologies like 3D mammography or MRI, acts as a key deterrent factor of the global market. In addition, limited access in rural and underserved areas due t%li%lack of healthcare infrastructure, trained professionals, and mobile screening units significantly restrains the market growth. On the contrary, innovations in imaging technologies, such as digital mammography, 3D mammography, and MRI, are enhancing the accuracy and efficiency of breast cancer screening. These advancements are making screening more accessible and reliable, which are expected t%li%offer remunerative opportunities for the expansion of the global market during the market. T%li%improve access t%li%breast cancer screening in remote and underserved areas, mobile mammography units are being introduced t%li%address the concern of limited access t%li%healthcare. Such initiatives are anticipated t%li%open new avenues for the market growth in the near future.
The global breast cancer screening industry is segmented int%li%test type, gender, end user, and region. By test type, the market is divided int%li%blood marker test, genetic test, imaging test, and immunohistochemistry test. According t%li%gender, it is divided int%li%male and female. As per end user, it is fragmented int%li%specialty clinics, hospitals, diagnostic centers, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
By test type, the imaging test segment dominated the market share in 2023.
According t%li%gender, the female segment exhibited the largest market share in 2023.
As per end user, hospital emerged as the leading segment, in terms of share, in 2023.
Region wise, North America holds a dominant position in 2023; however, Asia-Pacific is expected t%li%register highest CAGR during the forecast period.
Competition Analysis
Competitive analysis and profiles of the major players in the global breast cancer screening market include Siemens Healthineers AG, Myriad Genetics, Inc., Metabolomic Technologies Inc, Biocrates Lifesciences AG, A&G Pharmaceutical, Provista Diagnostics Inc, F. Hoffmann-La Roche AG, Volpara Health Limited, Quest Diagnostics Inc., and GE Healthcare. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships t%li%sustain the intense competition and gain a strong foothold in the global market.
Additional benefits you will get with this purchase are:
By Test Type
Breast cancer screening is a critical public health strategy aimed at early detection of breast cancer, the most common cancer among women globally. The primary goal of this preventative measure is t%li%identify cancer at an early stage when it is most treatable. Mammography is the most widely used screening tool, and its regular use has been shown t%li%reduce mortality rates from breast cancer. By detecting tumors early, breast cancer screening increases the chances of successful treatment, improves survival rates, and can help t%li%reduce the need for more aggressive treatments later on.
The growth of the global breast cancer screening market is driven by alarming increase in the global prevalence of breast cancer and rise in awareness and demand for early detection methods. According t%li%a study published in March 2024 by the World Health Organization, approximately 2.3 million women were diagnosed with breast cancer and 670,000 deaths were reported globally in 2022. Furthermore, governments and healthcare organizations are increasingly promoting breast cancer screening through awareness campaigns, subsidies, and organized screening programs, which have encouraged easy access t%li%screening services. According t%li%a study published by the U.S. Centers for Disease Control and Prevention in 2022, approximately 76.4% of women aged 50-74 underwent a mammogram within the past tw%li%years. This statistic reflects the effectiveness of public health campaigns and the accessibility of screening services across the U.S. Moreover, surge in aged women population significantly contributes toward the market growth. This is attributed t%li%the fact that aged women are at higher risk of developing breast cancer due t%li%weakened immune system, accumulation of genetic mutations, and changes in breast tissue. Rise in emphasis on early screening in younger women and development of non-invasive screening methods are the key trends are that further fostering the market growth. However, high cost associated with breast cancer screening, particularly advanced technologies like 3D mammography or MRI, acts as a key deterrent factor of the global market. In addition, limited access in rural and underserved areas due t%li%lack of healthcare infrastructure, trained professionals, and mobile screening units significantly restrains the market growth. On the contrary, innovations in imaging technologies, such as digital mammography, 3D mammography, and MRI, are enhancing the accuracy and efficiency of breast cancer screening. These advancements are making screening more accessible and reliable, which are expected t%li%offer remunerative opportunities for the expansion of the global market during the market. T%li%improve access t%li%breast cancer screening in remote and underserved areas, mobile mammography units are being introduced t%li%address the concern of limited access t%li%healthcare. Such initiatives are anticipated t%li%open new avenues for the market growth in the near future.
The global breast cancer screening industry is segmented int%li%test type, gender, end user, and region. By test type, the market is divided int%li%blood marker test, genetic test, imaging test, and immunohistochemistry test. According t%li%gender, it is divided int%li%male and female. As per end user, it is fragmented int%li%specialty clinics, hospitals, diagnostic centers, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
By test type, the imaging test segment dominated the market share in 2023.
According t%li%gender, the female segment exhibited the largest market share in 2023.
As per end user, hospital emerged as the leading segment, in terms of share, in 2023.
Region wise, North America holds a dominant position in 2023; however, Asia-Pacific is expected t%li%register highest CAGR during the forecast period.
Competition Analysis
Competitive analysis and profiles of the major players in the global breast cancer screening market include Siemens Healthineers AG, Myriad Genetics, Inc., Metabolomic Technologies Inc, Biocrates Lifesciences AG, A&G Pharmaceutical, Provista Diagnostics Inc, F. Hoffmann-La Roche AG, Volpara Health Limited, Quest Diagnostics Inc., and GE Healthcare. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships t%li%sustain the intense competition and gain a strong foothold in the global market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting t%li%16 analyst hours t%li%solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent t%li%3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
- Regulatory Guidelines
- Additional company profiles with specific t%li%client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
By Test Type
- Blood Marker Test
- Genetic Test
- Imaging Test
- Immunohistochemistry Test
- Male
- Female
- Specialty Clinics
- Hospitals
- Diagnostic Centers
- Other
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Siemens Healthineers AG
- Myriad Genetics, Inc.
- Metabolomic Technologies Inc
- Biocrates Lifesciences AG
- A&G Pharmaceutical
- Provista Diagnostics Inc
- F. Hoffmann-La Roche AG
- Volpara Health Limited
- Quest Diagnostics Inc.
- GE Healthcare
CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: BRUCELLOSIS VACCINES MARKET, BY TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Type
4.2. RBS1
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. S19
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. B19
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
CHAPTER 5: BRUCELLOSIS VACCINES MARKET, BY VACCINE
5.1. Market Overview
5.1.1 Market Size and Forecast, By Vaccine
5.2. DNA Vaccine
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Subunit Vaccine
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
5.4. Vector Vaccine
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, By Region
5.4.3. Market Share Analysis, By Country
5.5. Recombinant Vaccine
5.5.1. Key Market Trends, Growth Factors and Opportunities
5.5.2. Market Size and Forecast, By Region
5.5.3. Market Share Analysis, By Country
CHAPTER 6: BRUCELLOSIS VACCINES MARKET, BY ANIMAL TYPE
6.1. Market Overview
6.1.1 Market Size and Forecast, By Animal Type
6.2. Cattle
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Size and Forecast, By Region
6.2.3. Market Share Analysis, By Country
6.3. Sheep
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Size and Forecast, By Region
6.3.3. Market Share Analysis, By Country
6.4. Goat
6.4.1. Key Market Trends, Growth Factors and Opportunities
6.4.2. Market Size and Forecast, By Region
6.4.3. Market Share Analysis, By Country
CHAPTER 7: BRUCELLOSIS VACCINES MARKET, BY END USER
7.1. Market Overview
7.1.1 Market Size and Forecast, By End User
7.2. Veterinary Hospitals And Clinics
7.2.1. Key Market Trends, Growth Factors and Opportunities
7.2.2. Market Size and Forecast, By Region
7.2.3. Market Share Analysis, By Country
7.3. Animal Care Centers
7.3.1. Key Market Trends, Growth Factors and Opportunities
7.3.2. Market Size and Forecast, By Region
7.3.3. Market Share Analysis, By Country
7.4. Other
7.4.1. Key Market Trends, Growth Factors and Opportunities
7.4.2. Market Size and Forecast, By Region
7.4.3. Market Share Analysis, By Country
CHAPTER 8: BRUCELLOSIS VACCINES MARKET, BY REGION
8.1. Market Overview
8.1.1 Market Size and Forecast, By Region
8.2. North America
8.2.1. Key Market Trends and Opportunities
8.2.2. Market Size and Forecast, By Type
8.2.3. Market Size and Forecast, By Vaccine
8.2.4. Market Size and Forecast, By Animal Type
8.2.5. Market Size and Forecast, By End User
8.2.6. Market Size and Forecast, By Country
8.2.7. U.S. Brucellosis Vaccines Market
8.2.7.1. Market Size and Forecast, By Type
8.2.7.2. Market Size and Forecast, By Vaccine
8.2.7.3. Market Size and Forecast, By Animal Type
8.2.7.4. Market Size and Forecast, By End User
8.2.8. Canada Brucellosis Vaccines Market
8.2.8.1. Market Size and Forecast, By Type
8.2.8.2. Market Size and Forecast, By Vaccine
8.2.8.3. Market Size and Forecast, By Animal Type
8.2.8.4. Market Size and Forecast, By End User
8.2.9. Mexico Brucellosis Vaccines Market
8.2.9.1. Market Size and Forecast, By Type
8.2.9.2. Market Size and Forecast, By Vaccine
8.2.9.3. Market Size and Forecast, By Animal Type
8.2.9.4. Market Size and Forecast, By End User
8.3. Europe
8.3.1. Key Market Trends and Opportunities
8.3.2. Market Size and Forecast, By Type
8.3.3. Market Size and Forecast, By Vaccine
8.3.4. Market Size and Forecast, By Animal Type
8.3.5. Market Size and Forecast, By End User
8.3.6. Market Size and Forecast, By Country
8.3.7. Germany Brucellosis Vaccines Market
8.3.7.1. Market Size and Forecast, By Type
8.3.7.2. Market Size and Forecast, By Vaccine
8.3.7.3. Market Size and Forecast, By Animal Type
8.3.7.4. Market Size and Forecast, By End User
8.3.8. France Brucellosis Vaccines Market
8.3.8.1. Market Size and Forecast, By Type
8.3.8.2. Market Size and Forecast, By Vaccine
8.3.8.3. Market Size and Forecast, By Animal Type
8.3.8.4. Market Size and Forecast, By End User
8.3.9. UK Brucellosis Vaccines Market
8.3.9.1. Market Size and Forecast, By Type
8.3.9.2. Market Size and Forecast, By Vaccine
8.3.9.3. Market Size and Forecast, By Animal Type
8.3.9.4. Market Size and Forecast, By End User
8.3.10. Italy Brucellosis Vaccines Market
8.3.10.1. Market Size and Forecast, By Type
8.3.10.2. Market Size and Forecast, By Vaccine
8.3.10.3. Market Size and Forecast, By Animal Type
8.3.10.4. Market Size and Forecast, By End User
8.3.11. Spain Brucellosis Vaccines Market
8.3.11.1. Market Size and Forecast, By Type
8.3.11.2. Market Size and Forecast, By Vaccine
8.3.11.3. Market Size and Forecast, By Animal Type
8.3.11.4. Market Size and Forecast, By End User
8.3.12. Rest of Europe Brucellosis Vaccines Market
8.3.12.1. Market Size and Forecast, By Type
8.3.12.2. Market Size and Forecast, By Vaccine
8.3.12.3. Market Size and Forecast, By Animal Type
8.3.12.4. Market Size and Forecast, By End User
8.4. Asia-Pacific
8.4.1. Key Market Trends and Opportunities
8.4.2. Market Size and Forecast, By Type
8.4.3. Market Size and Forecast, By Vaccine
8.4.4. Market Size and Forecast, By Animal Type
8.4.5. Market Size and Forecast, By End User
8.4.6. Market Size and Forecast, By Country
8.4.7. Japan Brucellosis Vaccines Market
8.4.7.1. Market Size and Forecast, By Type
8.4.7.2. Market Size and Forecast, By Vaccine
8.4.7.3. Market Size and Forecast, By Animal Type
8.4.7.4. Market Size and Forecast, By End User
8.4.8. China Brucellosis Vaccines Market
8.4.8.1. Market Size and Forecast, By Type
8.4.8.2. Market Size and Forecast, By Vaccine
8.4.8.3. Market Size and Forecast, By Animal Type
8.4.8.4. Market Size and Forecast, By End User
8.4.9. Australia Brucellosis Vaccines Market
8.4.9.1. Market Size and Forecast, By Type
8.4.9.2. Market Size and Forecast, By Vaccine
8.4.9.3. Market Size and Forecast, By Animal Type
8.4.9.4. Market Size and Forecast, By End User
8.4.10. India Brucellosis Vaccines Market
8.4.10.1. Market Size and Forecast, By Type
8.4.10.2. Market Size and Forecast, By Vaccine
8.4.10.3. Market Size and Forecast, By Animal Type
8.4.10.4. Market Size and Forecast, By End User
8.4.11. South Korea Brucellosis Vaccines Market
8.4.11.1. Market Size and Forecast, By Type
8.4.11.2. Market Size and Forecast, By Vaccine
8.4.11.3. Market Size and Forecast, By Animal Type
8.4.11.4. Market Size and Forecast, By End User
8.4.12. Rest of Asia-Pacific Brucellosis Vaccines Market
8.4.12.1. Market Size and Forecast, By Type
8.4.12.2. Market Size and Forecast, By Vaccine
8.4.12.3. Market Size and Forecast, By Animal Type
8.4.12.4. Market Size and Forecast, By End User
8.5. LAMEA
8.5.1. Key Market Trends and Opportunities
8.5.2. Market Size and Forecast, By Type
8.5.3. Market Size and Forecast, By Vaccine
8.5.4. Market Size and Forecast, By Animal Type
8.5.5. Market Size and Forecast, By End User
8.5.6. Market Size and Forecast, By Country
8.5.7. Brazil Brucellosis Vaccines Market
8.5.7.1. Market Size and Forecast, By Type
8.5.7.2. Market Size and Forecast, By Vaccine
8.5.7.3. Market Size and Forecast, By Animal Type
8.5.7.4. Market Size and Forecast, By End User
8.5.8. Saudi Arabia Brucellosis Vaccines Market
8.5.8.1. Market Size and Forecast, By Type
8.5.8.2. Market Size and Forecast, By Vaccine
8.5.8.3. Market Size and Forecast, By Animal Type
8.5.8.4. Market Size and Forecast, By End User
8.5.9. South Africa Brucellosis Vaccines Market
8.5.9.1. Market Size and Forecast, By Type
8.5.9.2. Market Size and Forecast, By Vaccine
8.5.9.3. Market Size and Forecast, By Animal Type
8.5.9.4. Market Size and Forecast, By End User
8.5.10. Rest of LAMEA Brucellosis Vaccines Market
8.5.10.1. Market Size and Forecast, By Type
8.5.10.2. Market Size and Forecast, By Vaccine
8.5.10.3. Market Size and Forecast, By Animal Type
8.5.10.4. Market Size and Forecast, By End User
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top Winning Strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top Player Positioning, 2023
CHAPTER 10: COMPANY PROFILES
10.1. Ceva Poultry
10.1.1. Company Overview
10.1.2. Key Executives
10.1.3. Company Snapshot
10.1.4. Operating Business Segments
10.1.5. Product Portfolio
10.1.6. Business Performance
10.1.7. Key Strategic Moves and Developments
10.2. Colorado Serum Company
10.2.1. Company Overview
10.2.2. Key Executives
10.2.3. Company Snapshot
10.2.4. Operating Business Segments
10.2.5. Product Portfolio
10.2.6. Business Performance
10.2.7. Key Strategic Moves and Developments
10.3. Creative Biolabs
10.3.1. Company Overview
10.3.2. Key Executives
10.3.3. Company Snapshot
10.3.4. Operating Business Segments
10.3.5. Product Portfolio
10.3.6. Business Performance
10.3.7. Key Strategic Moves and Developments
10.4. CZ Vaccines
10.4.1. Company Overview
10.4.2. Key Executives
10.4.3. Company Snapshot
10.4.4. Operating Business Segments
10.4.5. Product Portfolio
10.4.6. Business Performance
10.4.7. Key Strategic Moves and Developments
10.5. Fivet Animal Health
10.5.1. Company Overview
10.5.2. Key Executives
10.5.3. Company Snapshot
10.5.4. Operating Business Segments
10.5.5. Product Portfolio
10.5.6. Business Performance
10.5.7. Key Strategic Moves and Developments
10.6. Hester Biosciences Limited
10.6.1. Company Overview
10.6.2. Key Executives
10.6.3. Company Snapshot
10.6.4. Operating Business Segments
10.6.5. Product Portfolio
10.6.6. Business Performance
10.6.7. Key Strategic Moves and Developments
10.7. Indian Immunologicals Ltd
10.7.1. Company Overview
10.7.2. Key Executives
10.7.3. Company Snapshot
10.7.4. Operating Business Segments
10.7.5. Product Portfolio
10.7.6. Business Performance
10.7.7. Key Strategic Moves and Developments
10.8. Jordan Bio-industries Center
10.8.1. Company Overview
10.8.2. Key Executives
10.8.3. Company Snapshot
10.8.4. Operating Business Segments
10.8.5. Product Portfolio
10.8.6. Business Performance
10.8.7. Key Strategic Moves and Developments
10.9. Laboratories Tornel
10.9.1. Company Overview
10.9.2. Key Executives
10.9.3. Company Snapshot
10.9.4. Operating Business Segments
10.9.5. Product Portfolio
10.9.6. Business Performance
10.9.7. Key Strategic Moves and Developments
10.10. Merck And Co., Inc.
10.10.1. Company Overview
10.10.2. Key Executives
10.10.3. Company Snapshot
10.10.4. Operating Business Segments
10.10.5. Product Portfolio
10.10.6. Business Performance
10.10.7. Key Strategic Moves and Developments
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: BRUCELLOSIS VACCINES MARKET, BY TYPE
4.1. Market Overview
4.1.1 Market Size and Forecast, By Type
4.2. RBS1
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. S19
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. B19
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
CHAPTER 5: BRUCELLOSIS VACCINES MARKET, BY VACCINE
5.1. Market Overview
5.1.1 Market Size and Forecast, By Vaccine
5.2. DNA Vaccine
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Subunit Vaccine
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
5.4. Vector Vaccine
5.4.1. Key Market Trends, Growth Factors and Opportunities
5.4.2. Market Size and Forecast, By Region
5.4.3. Market Share Analysis, By Country
5.5. Recombinant Vaccine
5.5.1. Key Market Trends, Growth Factors and Opportunities
5.5.2. Market Size and Forecast, By Region
5.5.3. Market Share Analysis, By Country
CHAPTER 6: BRUCELLOSIS VACCINES MARKET, BY ANIMAL TYPE
6.1. Market Overview
6.1.1 Market Size and Forecast, By Animal Type
6.2. Cattle
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Size and Forecast, By Region
6.2.3. Market Share Analysis, By Country
6.3. Sheep
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Size and Forecast, By Region
6.3.3. Market Share Analysis, By Country
6.4. Goat
6.4.1. Key Market Trends, Growth Factors and Opportunities
6.4.2. Market Size and Forecast, By Region
6.4.3. Market Share Analysis, By Country
CHAPTER 7: BRUCELLOSIS VACCINES MARKET, BY END USER
7.1. Market Overview
7.1.1 Market Size and Forecast, By End User
7.2. Veterinary Hospitals And Clinics
7.2.1. Key Market Trends, Growth Factors and Opportunities
7.2.2. Market Size and Forecast, By Region
7.2.3. Market Share Analysis, By Country
7.3. Animal Care Centers
7.3.1. Key Market Trends, Growth Factors and Opportunities
7.3.2. Market Size and Forecast, By Region
7.3.3. Market Share Analysis, By Country
7.4. Other
7.4.1. Key Market Trends, Growth Factors and Opportunities
7.4.2. Market Size and Forecast, By Region
7.4.3. Market Share Analysis, By Country
CHAPTER 8: BRUCELLOSIS VACCINES MARKET, BY REGION
8.1. Market Overview
8.1.1 Market Size and Forecast, By Region
8.2. North America
8.2.1. Key Market Trends and Opportunities
8.2.2. Market Size and Forecast, By Type
8.2.3. Market Size and Forecast, By Vaccine
8.2.4. Market Size and Forecast, By Animal Type
8.2.5. Market Size and Forecast, By End User
8.2.6. Market Size and Forecast, By Country
8.2.7. U.S. Brucellosis Vaccines Market
8.2.7.1. Market Size and Forecast, By Type
8.2.7.2. Market Size and Forecast, By Vaccine
8.2.7.3. Market Size and Forecast, By Animal Type
8.2.7.4. Market Size and Forecast, By End User
8.2.8. Canada Brucellosis Vaccines Market
8.2.8.1. Market Size and Forecast, By Type
8.2.8.2. Market Size and Forecast, By Vaccine
8.2.8.3. Market Size and Forecast, By Animal Type
8.2.8.4. Market Size and Forecast, By End User
8.2.9. Mexico Brucellosis Vaccines Market
8.2.9.1. Market Size and Forecast, By Type
8.2.9.2. Market Size and Forecast, By Vaccine
8.2.9.3. Market Size and Forecast, By Animal Type
8.2.9.4. Market Size and Forecast, By End User
8.3. Europe
8.3.1. Key Market Trends and Opportunities
8.3.2. Market Size and Forecast, By Type
8.3.3. Market Size and Forecast, By Vaccine
8.3.4. Market Size and Forecast, By Animal Type
8.3.5. Market Size and Forecast, By End User
8.3.6. Market Size and Forecast, By Country
8.3.7. Germany Brucellosis Vaccines Market
8.3.7.1. Market Size and Forecast, By Type
8.3.7.2. Market Size and Forecast, By Vaccine
8.3.7.3. Market Size and Forecast, By Animal Type
8.3.7.4. Market Size and Forecast, By End User
8.3.8. France Brucellosis Vaccines Market
8.3.8.1. Market Size and Forecast, By Type
8.3.8.2. Market Size and Forecast, By Vaccine
8.3.8.3. Market Size and Forecast, By Animal Type
8.3.8.4. Market Size and Forecast, By End User
8.3.9. UK Brucellosis Vaccines Market
8.3.9.1. Market Size and Forecast, By Type
8.3.9.2. Market Size and Forecast, By Vaccine
8.3.9.3. Market Size and Forecast, By Animal Type
8.3.9.4. Market Size and Forecast, By End User
8.3.10. Italy Brucellosis Vaccines Market
8.3.10.1. Market Size and Forecast, By Type
8.3.10.2. Market Size and Forecast, By Vaccine
8.3.10.3. Market Size and Forecast, By Animal Type
8.3.10.4. Market Size and Forecast, By End User
8.3.11. Spain Brucellosis Vaccines Market
8.3.11.1. Market Size and Forecast, By Type
8.3.11.2. Market Size and Forecast, By Vaccine
8.3.11.3. Market Size and Forecast, By Animal Type
8.3.11.4. Market Size and Forecast, By End User
8.3.12. Rest of Europe Brucellosis Vaccines Market
8.3.12.1. Market Size and Forecast, By Type
8.3.12.2. Market Size and Forecast, By Vaccine
8.3.12.3. Market Size and Forecast, By Animal Type
8.3.12.4. Market Size and Forecast, By End User
8.4. Asia-Pacific
8.4.1. Key Market Trends and Opportunities
8.4.2. Market Size and Forecast, By Type
8.4.3. Market Size and Forecast, By Vaccine
8.4.4. Market Size and Forecast, By Animal Type
8.4.5. Market Size and Forecast, By End User
8.4.6. Market Size and Forecast, By Country
8.4.7. Japan Brucellosis Vaccines Market
8.4.7.1. Market Size and Forecast, By Type
8.4.7.2. Market Size and Forecast, By Vaccine
8.4.7.3. Market Size and Forecast, By Animal Type
8.4.7.4. Market Size and Forecast, By End User
8.4.8. China Brucellosis Vaccines Market
8.4.8.1. Market Size and Forecast, By Type
8.4.8.2. Market Size and Forecast, By Vaccine
8.4.8.3. Market Size and Forecast, By Animal Type
8.4.8.4. Market Size and Forecast, By End User
8.4.9. Australia Brucellosis Vaccines Market
8.4.9.1. Market Size and Forecast, By Type
8.4.9.2. Market Size and Forecast, By Vaccine
8.4.9.3. Market Size and Forecast, By Animal Type
8.4.9.4. Market Size and Forecast, By End User
8.4.10. India Brucellosis Vaccines Market
8.4.10.1. Market Size and Forecast, By Type
8.4.10.2. Market Size and Forecast, By Vaccine
8.4.10.3. Market Size and Forecast, By Animal Type
8.4.10.4. Market Size and Forecast, By End User
8.4.11. South Korea Brucellosis Vaccines Market
8.4.11.1. Market Size and Forecast, By Type
8.4.11.2. Market Size and Forecast, By Vaccine
8.4.11.3. Market Size and Forecast, By Animal Type
8.4.11.4. Market Size and Forecast, By End User
8.4.12. Rest of Asia-Pacific Brucellosis Vaccines Market
8.4.12.1. Market Size and Forecast, By Type
8.4.12.2. Market Size and Forecast, By Vaccine
8.4.12.3. Market Size and Forecast, By Animal Type
8.4.12.4. Market Size and Forecast, By End User
8.5. LAMEA
8.5.1. Key Market Trends and Opportunities
8.5.2. Market Size and Forecast, By Type
8.5.3. Market Size and Forecast, By Vaccine
8.5.4. Market Size and Forecast, By Animal Type
8.5.5. Market Size and Forecast, By End User
8.5.6. Market Size and Forecast, By Country
8.5.7. Brazil Brucellosis Vaccines Market
8.5.7.1. Market Size and Forecast, By Type
8.5.7.2. Market Size and Forecast, By Vaccine
8.5.7.3. Market Size and Forecast, By Animal Type
8.5.7.4. Market Size and Forecast, By End User
8.5.8. Saudi Arabia Brucellosis Vaccines Market
8.5.8.1. Market Size and Forecast, By Type
8.5.8.2. Market Size and Forecast, By Vaccine
8.5.8.3. Market Size and Forecast, By Animal Type
8.5.8.4. Market Size and Forecast, By End User
8.5.9. South Africa Brucellosis Vaccines Market
8.5.9.1. Market Size and Forecast, By Type
8.5.9.2. Market Size and Forecast, By Vaccine
8.5.9.3. Market Size and Forecast, By Animal Type
8.5.9.4. Market Size and Forecast, By End User
8.5.10. Rest of LAMEA Brucellosis Vaccines Market
8.5.10.1. Market Size and Forecast, By Type
8.5.10.2. Market Size and Forecast, By Vaccine
8.5.10.3. Market Size and Forecast, By Animal Type
8.5.10.4. Market Size and Forecast, By End User
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top Winning Strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top Player Positioning, 2023
CHAPTER 10: COMPANY PROFILES
10.1. Ceva Poultry
10.1.1. Company Overview
10.1.2. Key Executives
10.1.3. Company Snapshot
10.1.4. Operating Business Segments
10.1.5. Product Portfolio
10.1.6. Business Performance
10.1.7. Key Strategic Moves and Developments
10.2. Colorado Serum Company
10.2.1. Company Overview
10.2.2. Key Executives
10.2.3. Company Snapshot
10.2.4. Operating Business Segments
10.2.5. Product Portfolio
10.2.6. Business Performance
10.2.7. Key Strategic Moves and Developments
10.3. Creative Biolabs
10.3.1. Company Overview
10.3.2. Key Executives
10.3.3. Company Snapshot
10.3.4. Operating Business Segments
10.3.5. Product Portfolio
10.3.6. Business Performance
10.3.7. Key Strategic Moves and Developments
10.4. CZ Vaccines
10.4.1. Company Overview
10.4.2. Key Executives
10.4.3. Company Snapshot
10.4.4. Operating Business Segments
10.4.5. Product Portfolio
10.4.6. Business Performance
10.4.7. Key Strategic Moves and Developments
10.5. Fivet Animal Health
10.5.1. Company Overview
10.5.2. Key Executives
10.5.3. Company Snapshot
10.5.4. Operating Business Segments
10.5.5. Product Portfolio
10.5.6. Business Performance
10.5.7. Key Strategic Moves and Developments
10.6. Hester Biosciences Limited
10.6.1. Company Overview
10.6.2. Key Executives
10.6.3. Company Snapshot
10.6.4. Operating Business Segments
10.6.5. Product Portfolio
10.6.6. Business Performance
10.6.7. Key Strategic Moves and Developments
10.7. Indian Immunologicals Ltd
10.7.1. Company Overview
10.7.2. Key Executives
10.7.3. Company Snapshot
10.7.4. Operating Business Segments
10.7.5. Product Portfolio
10.7.6. Business Performance
10.7.7. Key Strategic Moves and Developments
10.8. Jordan Bio-industries Center
10.8.1. Company Overview
10.8.2. Key Executives
10.8.3. Company Snapshot
10.8.4. Operating Business Segments
10.8.5. Product Portfolio
10.8.6. Business Performance
10.8.7. Key Strategic Moves and Developments
10.9. Laboratories Tornel
10.9.1. Company Overview
10.9.2. Key Executives
10.9.3. Company Snapshot
10.9.4. Operating Business Segments
10.9.5. Product Portfolio
10.9.6. Business Performance
10.9.7. Key Strategic Moves and Developments
10.10. Merck And Co., Inc.
10.10.1. Company Overview
10.10.2. Key Executives
10.10.3. Company Snapshot
10.10.4. Operating Business Segments
10.10.5. Product Portfolio
10.10.6. Business Performance
10.10.7. Key Strategic Moves and Developments
